DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.03 -0.21 (-0.29%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
by Zacks Equity Research
Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.
Varian & Tata Trust Tie Up to Boost Radiotherapy in India
by Zacks Equity Research
Varian's (VAR) three-year deal with Tata Trust is likely to fortify its foothold in the Asia-Pacific radiotherapy space.
The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
The Best And Worst Stocks of the 10-Year Bull Market
by Tirthankar Chakraborty
We highlight some of the best and worst stocks over the bull market's 10 years.
HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
Align Technology-Benco Dental Deal to Expand iTero Reach
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
GNC Holdings to Expand Portfolio With Alani Nutrition Deal
by Zacks Equity Research
With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.
Tandem's Global Growth a Boost, Operating Losses a Bane
by Zacks Equity Research
Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.
GNC Forms Joint Venture With IVC to Improve Cost Efficiency
by Zacks Equity Research
The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.
Hologic (HOLX) Receives Global Nods for Omni Hysteroscope
by Zacks Equity Research
Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
DexCom (DXCM) Gets Health Canada Approval for G6 CGM System
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Here's Why Investors Should Buy DexCom (DXCM) Stock Now
by Zacks Equity Research
Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.
DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) continues to gain on solid international business.
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 237.50% and 2.18%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
by Zacks Equity Research
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
Luminex Hurt By Segmental Sluggishness, Stiff Competition
by Zacks Equity Research
Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance
by Zacks Equity Research
Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.